Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosisBlinded central review ...

Galectin Therapeutics (GALT) announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and ...

These animals develop cirrhosis, portal hypertension, and HPS at 4–5 weeks after surgery. Most other animal models of cirrhosis, such as that induced by carbon tetrachloride, have not proved ...

Cirrhotic portal hypertension is characterised by development of the decompensating events of ascites, encephalopathy, portal hypertensive bleeding and hepatorenal syndrome, which arise in a setting ...

There is a growing global burden of liver disease with the current management for complications of liver cirrhosis being reactive as opposed to proactive, affecting outcomes. Management can often be ...

Serum zinc is often deficient in patients with liver cirrhosis and hepatic encephalopathy (HE), according to a study published online in the September issue of the Journal of Family Medicine and ...

A doctor from Sancti Spíritus took to social media this Tuesday to express her anger over the exorbitant cost of powdered ...

此外，通过宏基因组学特征与代谢组学特征，研究人员构建了联合模型，并显示出良好的诊断性能，在测试集上的AUC为0.97。在外部独立验证队列上的AUC为0.88。与Baveno ...

点击下载PDF原文引用本文Guo G, Yang W, Li J, Yang Z, Liang J, Sun C. The Development and Appraisal of MELD 3.0 in Liver Diseases: Good Things Never Come Easy. J Clin Transl Hepatol. Published online: Nov 12, 202 ...

25, 2024 — Researchers discovered liver resident macrophages' pivotal role in defending against gut bacteria and related substances entering via the portal ... to liver cirrhosis and other ...

Purpose Published evidence on the incidence and predictors of venous thromboembolism (VTE) in patients with cirrhosis of the liver is reviewed. Summary The frequently observed phenomenon of ...